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A B S T R A C T
Leishmaniasis is a serious medical issue in many countries around the World, but it remains largely neglected in
terms of research investment for developing new control and treatment measures. No vaccines exist for human
use, and the chemotherapeutic agents currently used are scanty. Furthermore, for some drugs, resistance and
treatment failure are increasing to alarming levels. The aim of this work was to identify genomic and tran-
criptomic alterations associated with experimental resistance against the common drugs used against VL: tri-
valent antimony (SbIII, S line), amphotericin B (AmB, A line), miltefosine (MIL, M line) and paromomycin (PMM,
P line). A total of 1006 diﬀerentially expressed transcripts were identiﬁed in the S line, 379 in the A line, 146 in
the M line, and 129 in the P line. Also, changes in ploidy of chromosomes and ampliﬁcation/deletion of par-
ticular regions were observed in the resistant lines regarding the parental one. A series of genes were identiﬁed
as possible drivers of the resistance phenotype and were validated in both promastigotes and amastigotes from
Leishmania donovani, Leishmania infantum and Leishmania major species. Remarkably, a deletion of the gene
LinJ.36.2510 (coding for 24-sterol methyltransferase, SMT) was found to be associated with AmB-resistance in
the A line. In the P line, a dramatic overexpression of the transcripts LinJ.27.T1940 and LinJ.27.T1950 that
results from a massive ampliﬁcation of the collinear genes was suggested as one of the mechanisms of PMM
resistance. This conclusion was reinforced after transfection experiments in which signiﬁcant PMM-resistance
was generated in WT parasites over-expressing either gene LinJ.27.1940 (coding for a D-lactate dehydrogenase-
like protein, D-LDH) or gene LinJ.27.1950 (coding for an aminotransferase of branched-chain amino acids,
BCAT). This work allowed to identify new drivers, like SMT, the deletion of which being associated with re-
sistance to AmB, and the tandem D-LDH-BCAT, the ampliﬁcation of which being related to PMM resistance.
1. Introduction
Leishmaniasis is a complex of diseases caused by protists of the
genus Leishmania. Many species of this genus are human pathogens and
are responsible for diﬀerent clinical forms of the disease, among others
cutaneous (CL), mucosal and visceral leishmaniasis (VL). These in-
fectious diseases are endemic worldwide, in tropical and sub-tropical
regions, including also the Mediterranean basin (Dujardin et al., 2008).
Recent estimates indicate that there are approximately 0.4 million new
VL cases and 1.2 million CL cases every year (Alvar et al., 2012).
Moreover, the prevalence of VL co-infection with human
immunodeﬁciency virus (HIV) is increasing, and HIV infection can in-
crease the risk of patients to develop VL, reducing their ability to re-
spond to chemotherapy, and increasing the probability of disease re-
lapse (van Griensven et al., 2014). Unfortunately, there are currently no
eﬀective vaccines against this parasite (Singh and Sundar, 2012). Thus,
control of leishmaniasis relies primarily on chemotherapy and vector
control (Singh et al., 2012). However, available drugs are limited in
number, and toxicity together with emerging resistance might further
jeopardize their use (Ouellette et al., 2004). Understanding drug re-
sistance is important to protect the few existing compounds, but also for
developing new ones (Hefnawy et al., 2017).
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Drug resistance phenotype can be the result of diﬀerent strategies
followed by Leishmania (reviewed in (Ouellette et al., 2004)), including:
decrease in drug uptake, eﬄux of drugs, inactivation of drugs (once
inside the parasite), loss of drug activation pathways, alteration of drug
targets, and ﬁnally the parasite may become more proﬁcient in re-
pairing drug damage. In addition, molecular adaptations related to drug
resistance may provide some advantages to Leishmania donovani para-
sites that may be counterintuitive, such as a higher capacity to survive
in stress conditions (Garcia-Hernandez et al., 2015), and an increased
ﬁtness (Vanaerschot et al., 2014).
Antimonials (Glucantime and Pentostam, SbV) were the ﬁrst drugs
used for treatment of leishmaniasis, almost eighty years ago and they
continue being a standard ﬁrst-line treatment in many places of the
world. However, the appearance of resistant parasites has been de-
scribed frequently in many endemic regions (Croft et al., 2006; Singh
et al., 2012; Hefnawy et al., 2017). Several membrane transporters of
the ABC superfamily have been involved in SbV resistance. PGPA/
MRPA (ABCC3), was the ﬁrst ABC transporter described to be re-
sponsible for clinical resistance to antimonials in L. donovani (Mittal
et al., 2007; Mukherjee et al., 2007; Mukhopadhyay et al., 2011) and
experimental resistance to trivalent antimony (SbIII) or the related
metal AsIII in L. tarentolae (Legare et al., 2001). The second ABC protein
involved in antimony resistance is PRP1 (ABCC7) (Coelho et al., 2003;
Leprohon et al., 2009). Recently, two other ABC transporters, ABCI4
and ABCG2 (Manzano et al., 2013; Perea et al., 2016), have been in-
volved in antimony resistance in L. major. These ABC transporters
confer resistance to antimony due to a signiﬁcant decrease in drug
accumulation as a consequence of an eﬄux of metals, probably con-
jugated with thiols. Other mechanisms involved in SbV resistance in L.
donovani include decreased drug uptake through inactivation of AQP1
(aquaglyceroporin) transporter, increased tolerance to oxidative stress
through upregulation of antioxidant pathways (increase in thiol levels)
and modiﬁcations in membrane ﬂuidity (Sundar, 2001; Decuypere
et al., 2005; Croft et al., 2006; Mittal et al., 2007; Imamura et al., 2016).
In recent years, a few other drugs have been used for treatment of
leishmaniasis, including amphotericin B liposome formulation
(AmBisome, AmB), oral miltefosine (MIL) and a parenteral formulation
of aminosidine (paromomycin, PMM) (reviewed in (Croft et al., 2006;
Monge-Maillo and Lopez-Velez, 2013; Sundar and Singh, 2016)).
However, resistance was also reported for these drugs: (i) experimental
resistance in L. donovani to AmB (Mbongo et al., 1998), MIL (Perez-
Victoria et al., 2003b; Seifert et al., 2003) and PMM (Maarouf et al.,
1998; Jhingran et al., 2009), and (ii) clinical resistance in L. donovani to
AmB (Purkait et al., 2012, 2015) and in L. infantum and L. donovani to
MIL (Mondelaers et al., 2016; Srivastava et al., 2017). Molecular me-
chanisms of AmB resistance of one clinical isolate of L. donovani have
been described including an altered membrane composition (decreased
ergosterol content) due to a modiﬁed expression of the two transcripts
coding for the enzyme S-adenosyl-L-methionine: C24-sterol methyl-
tranferase (SMT); the parasites show a decreased AmB aﬃnity and
uptake (Purkait et al., 2012). Additionally, the involvement of SMT in
AmB susceptibility has been validated in yeast (Konecna et al., 2016). A
recent publication has demonstrated that a mutation in the sterol 14-α-
demethylase, another enzyme of the sterol biosynthetic pathway, leads
to AmB resistance in Leishmania mexicana (Mwenechanya et al., 2017),
supporting the relevance of sterol biosynthetic pathway in AmB sus-
ceptibility. Also, the expression of ABCB (ABCB4, MDR1) transporter
was found to be higher in AmB resistant parasites, suggesting a high
eﬄux of AmB (Purkait et al., 2012). In addition, upregulation of thiol
metabolism and reduced intracellular thiol levels have been described
in clinical isolates of L. donovani resistant to AmB (Purkait et al., 2012;
Suman et al., 2016). MIL is the latest and unique oral antileishmanial
drug; however, after a decade of use, recent reports indicate a sig-
niﬁcant decrease in its eﬃcacy against VL (Rijal et al., 2013). Experi-
mental resistance to MIL was easily obtained (Seifert et al., 2003; Perez-
Victoria et al., 2003a). L. donovani resistant parasites showed changes in
the length and levels of unsaturation of fatty acids, reduction in er-
gosterol levels (Rakotomanga et al., 2005) and a signiﬁcant reduction
in drug internalization due to mutations in the MIL transporter genes
LdMT and/or LdRos3 (Perez-Victoria et al., 2003b; Sanchez-Cañete
et al., 2009). Only two clinical isolates with demonstrated MIL re-
sistance have been described, corresponding to L. infantum lines iso-
lated from HIV-coinfected patients in France that show a MIL-resistant
phenotype due to a frameshift mutation in the MIL transporter gene
LiRos3 and/or SNPs in the LiMT gene (Mondelaers et al., 2016). PMM, a
natural aminoglycoside antibiotic, has a high promising eﬃciency
against VL and CL. Although rapid development of experimental re-
sistance to PMM in L. donovani and L. infantum has been described
(Maarouf et al., 1998; Jhingran et al., 2009; Hendrickx et al., 2015), no
clinical resistant isolates to PMM have been reported, probably by its
low routine use in the ﬁeld. An increased membrane ﬂuidity associated
with a decreased intracellular PMM accumulation have been described
in experimental PMM resistant L. donovani lines (Jhingran et al., 2009;
Bhandari et al., 2014). Additionally, an increased expression of ABC
transporters (MDR1 and MRPA) and protein phosphatase 2A was ob-
served, together with an increased drug eﬄux and a greater tolerance of
L. donovani parasites to host defense mechanisms including nitrosative,
oxidative and complement-mediated stresses (Bhandari et al., 2014).
Next-generation sequencing (NGS) technologies are being used for
expediting the untargeted identiﬁcation of drug resistance markers in
many organisms, and also in Leishmania (reviewed in (Leprohon et al.,
2015)). In the absence of transcriptional regulation, a common strategy
of the parasite is to modulate gene dosage (Requena, 2011; Berg et al.,
2013), either locally by gene copy number variation (Inga et al., 1998)
and/or by generating episomal amplicons (Beverley, 1991) or at whole
chromosome level through aneuploidy (Sterkers et al., 2012; Imamura
et al., 2016). Recently, a combination of genome-wide cosmid-based
functional screening with NGS, termed as Cosmid Sequencing (Cos-Seq)
has been successfully used for identiﬁcation of drug target and re-
sistance mechanisms in Leishmania (Gazanion et al., 2016). However,
this method can only identify gain-of-function and individual loci in-
volved in drug resistance. Drug resistance selection by progressive in-
crease of exposure to the compound followed by NGS of both whole
DNA and mRNA remains the most adequate method for identifying
multi-genic adaptations in a broad context, including loss-of-function.
In present study, this method was applied on a same L. donovani line
allowing to study experimental resistance to either SbIII, AmB, MIL or
PMM, within a same genetic background. Chromosomal reorganiza-
tions and substantial changes in gene expression were found to be as-
sociated with the diﬀerent drug resistances. We further validated the
contribution of selected drug resistance markers, allowing us to identify
drivers of resistance to some drugs currently in use to treat leishma-
niasis.
2. Materials and methods
2.1. Chemicals
Trivalent antimony (SbIII), paromomycin (PMM), amphotericin B
(AmB), Triton X-100, paraformaldehyde, MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide], rhodamine 123 (Rh123),
phorbol 12-myristate 13-acetate (PMA), Trizol (TRI) Reagent, were
obtained from Sigma-Aldrich (St. Louis, MO). Miltefosine (MIL) was
purchased from Zentaris GmbH (Frankfurt am Main, Germany).
Hygromycin B (HyB), CellTracker, dichlorodihydroﬂuorescein diace-
tate (H2DCFDA), MitoSOX red, and 4’, 6-diamidino-2-phenylindole di-
hydrochloride (DAPI) were purchased from Invitrogen (Carlsbad, CA).
Geneticin G418 Sulphate, L-glutamine, and penicillin/streptomycin
were obtained from Gibco. Nourseothricin was obtained from Werner
Biogents. All chemicals were of the highest quality available.
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2.2. Leishmania culture conditions
Promastigotes of Leishmania donovani (MHOM/ET/67/HU3 and
MHOM/IND/80/Dd8), Leishmania major (MHOM/JL/80/Friedlin),
Leishmania infantum JPCM5 (MCAN/ES/98/LLM-877), and derivative
lines used in this study were grown at 28 °C in RPMI 1640-modiﬁed
medium (Invitrogen) supplemented with 20% heat-inactivated fetal
bovine serum (HIFBS, Invitrogen) and stored in cryobanks. Leishmania
lines overexpressing D-lactate dehydrogenase-like (D-LDH), branched-
chain amino acid aminotransferase (BCAT), protein associated with
diﬀerentiation (PAD), and sterol 24-c-methyltransferase (SMT) were
obtained in this study and grown in the same medium in the presence of
100 μg/ml of HyB. In a previous work (Garcia-Hernandez et al., 2012),
the lines A, M, P, and S (that are resistant to AmB, MIL, PMM, and SbIII,
respectively) were selected in vitro from L. donovani HU3 promastigotes
by a stepwise adaptation process till 80 μM SbIII, 0.1 μM AmB, 8 μMMIL
and 20 μM PMM. Wild-type (WT) and resistant lines were grown during
30 passages under drug pressure before proceeding with extraction of
both DNA and RNA for NGS sequencing. However, for the rest of pur-
poses, the lines were cultured without drugs just before being subjected
to the diﬀerent assays.
2.3. Isolation of DNA and RNA
Around 4×108 promastigotes in the late logarithmic phase were
harvested by centrifugation, and the pellet suspended in 1ml of Trizol
(TRI Reagent, Sigma-Aldrich, product No. T9424). Manufacturer's in-
structions were followed. Samples were kept at −70 °C for a week
before proceeding with the phase separation. After thawing, 0.2ml of
chloroform was added, and the mixtures were shaken vigorously for
15 s. After centrifugation, three phases were observed: a red organic
phase (containing protein), an interphase (containing DNA), and a
colorless upper aqueous phase (containing RNA). Both interphase and
aqueous phases were processed separately for isolation of DNA and
RNA, respectively. RNA samples were suspended in DEPC-treated
water, and their concentrations were determined using the Nanodrop
ND-1000 (Thermo Scientiﬁc); all samples showed A260/A280 ratios
higher than 2.0. In addition, RNA integrity was checked in a bioana-
lyzer (Agilent 2100). The DNA samples were also quantiﬁed by absor-
bance at 260 nm using the Nanodrop, and the integrity by electro-
phoresis in an 0.8% agarose gel.
2.4. Next-generation sequencing
Library preparations (mRNA and DNA) and sequencing were per-
formed by Centro de Análisis Genómico (CNAG, Spain). Sequencing was
done using Illumina HiSeq 2000 technology. From RNA libraries, paired
reads of 75 nucleotides were obtained, whereas 2× 100 reads were
obtained from DNA libraries. Sequence quality metrics were assessed
using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/).
2.5. Mapping of RNA-Seq and DNA-Seq reads to reference genomes
Reads were mapped to the reference genomes (v.9; TriTrypDB.org)
of L. infantum (JPCM5 strain (Peacock et al., 2007)) and L. donovani
(MHOM/NP/03/BPK282/0; clone BPK282/0cl4 (Downing et al.,
2011)) genomes using Bowtie2 with default parameters (Langmead and
Salzberg, 2012). This aligner was chosen because the end-to-end mode
has a better performance when working with a genome containing a
high level of repeated regions such as tandemly repeated genes. Other
aligners, by default, trim the reads to try to map as much reads as
possible, and consequently produce an over-representation of repeated
regions. As percentages of mapped reads were higher against the L.
infantum genome than against the L. donovani one, the former was used
as reference for subsequent analyses.
2.6. Assignment of RNA-Seq to speciﬁc transcripts and determination of
diﬀerentially expressed transcripts
L. infantum (JPCM5 strain) transcriptome was delineated using
RNA-Seq data derived from poly-A enriched RNA of log-phase pro-
mastigotes following the procedure described elsewhere (Rastrojo et al.,
2013). Afterwards, the HTSeq program (v0.6.1 (Anders et al., 2015))
was used for counting the reads overlapping with the transcripts (mode:
intersection-nonempty). These sets of values (3 replicates for each
sample) were used for diﬀerential expression analysis by the DESeq2
program (v1.8.1 (Love et al., 2014)).
2.7. Chromosome ploidy analysis and determination of chromosomal
alterations
The Illumina DNA-Seq reads were aligned to the L. infantum re-
ference genome by Bowtie2 (parameters: –np 0 –n-ceil L,0,0.02 –rdg 0,6
–rfg 0,6 –mp 6,2 –score-min L,0,-0.06 –no-unal). SAMtools view (Li
et al., 2009) (parameters: -Sh -f 2 -F 256) was used to discard multi-hit
reads, and an in-house script was used to discard orphan reads. Again,
SAMtools view was used to obtain the alignments in standard BAM
format and to count the number of reads (parameters: -F 0x4). After-
wards, the data in BAM format were analyzed by genomeCoverageBed
(BEDTools (Quinlan and Hall, 2010)) using the parameter –d to obtain
the read depth per position along each chromosome and the genome.
This procedure was repeated for each DNA-Seq sample (WT, S, A, M and
P lines). A normalization of coverage values was done taking into ac-
count the total number of reads for each sample. In the P line, due to the
over-ampliﬁcation of the genomic region 857320–865727 of chromo-
some 27, this region was not considered for the calculation of the mean
coverage of this chromosome. The somy of each chromosome was
calculated with the following formula 2*di/dm (Mondelaers et al.,
2016), where di is the median read depth of each chromosome and dm
is the median depth of the genome.
For analyzing the read coverage in particular genomic regions,
genomeCoverageBed (parameter –d) was again used to obtain the
coverage by position in the selected genomic regions. Afterwards, an in-
house Perl script was used to smooth read-depth values using over-
lapping windows of 5-Kb in length. For comparison between diﬀerent
samples, a further normalization considering the total number of reads
was applied. Finally, graphs were generated from the coverage values
by the tool plotly included in the R package (https://CRAN.R-project.
org). Figure drawing was done using the software Inkscape (https://
www.inkscape.org).
2.8. Gene cloning and transfection experiments
DNA fragments coding for D-LDH (LinJ.27.1940), BCAT
(LinJ.27.1950), PAD (LinJ.13.1430), and SMT (LinJ.36.2510) were
PCR ampliﬁed from genomic DNA of the L. donovani HU3 strain using
the following primer pairs:
LDHBamHIF 5′-TATGGATCCA TGACGTACCC ACTGAAACA-3′ and
LDHXbaIR 5′-ATATTCTAGA TTACAGGTGT GCCGTCGGGT-3′ for D-
LDH; BCABglIIF; 5′-ATATAGATCT ATGCTGCTGA GCCGACGCTG-3′
and BCAXbaIR 5′-ATATTCTAGA AGCCTCAACC TTCACTGACC-3′ for
BCAT; PADBglIIF 5′-ATATAGATCT ATGTTTGACA TTCGCGAGAA-3′
and PADXbaIR 5′-ATATTCTAGA CTACAGTGTC GTCTCCGGAG-3′ for
PAD and, SMTBglIIF 5′-ATATAGATCT ATGTCCGCCG GTGGCCGTGA-3′
and SMTXbaIR 5′- ATATTCTAGA CTAAGCCTGC TTGGACGGCT-3′ for
SMT. Restriction sites (in bold) were added for subsequent cloning. The
PCR products were subcloned and sequenced into the pLEXSY-hyg2
expression vector (Jenabioscience, Jena, Germany) and pIR1SAT ex-
pression vector (from Prof S.M. Beverley, Washington University, USA),
to generate the pLEXSY-DLDH, pLEXSY-BCAT, pLEXSY-PAD, pLEXSY-
SMT, pIR1SAT-DLDH, and pIR1SAT-BCAT constructs, respectively.
These plasmids were subsequently used for transfection of Leishmania
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promastigotes by electroporation in 2-mm gap cuvettes at 450 V and
500 μF (BTX Electro Cell Manipulator 600). Transfectants were selected
in medium containing Hyg (100 μg/ml) for pLEXSY-hyg2 or nourseo-
thricin (100 μg/ml) for pIR1SAT. The A line transfected with pLEXSY-
hyg2 empty and WT line transfected with pLEXSY-hyg2 empty and co-
transfected with both pLEXSY-hyg2 and pIR1SAT empty (controls) were
named as A + Lexsy, WT + Lexsy and WT + Lexsy + pIRSAT, re-
spectively, while WT line transfected with pLEXSY-DLDH, pLEXSY-
BCAT and pLEXSY-PAD, and co-transfected with pLEXSY-
DLDH + pIR1SAT-BCAT, and pLEXSY-BCAT + pIR1SAT-DLDH were
named as WT + D-LDH, WT + BCAT, WT + PAD,
WT + DLDH + BCAT, and WT + BCAT + DLDH, respectively. On the
other hand, the A line transfected with pLEXSY-SMT was named as
A + SMT.
For PCR ampliﬁcation of the locus expanding genes LinJ.36.2510
and LinJ.36.2520, the following primers were used: gSMT-Fw, 5′-
AAAGTTGGTG GCAACCTCC-3’; and gSMT-Rv, 5′- CCCAGGCAAG ACC
ACCTTAC-3’. As template, 25 ng of genomic DNA from either WT or A
lines were employed, and the cycling conditions were: 98 °C for 30 s,
followed by 30 cycles of 98 °C for 10 s, 65 °C for 20s and 72 °C for 3min,
and a ﬁnal extension step of 10min at 72 °C. Phusion Hot Start II High
Fidelity DNA Polymerase (Thermo Scientiﬁc) was used. The 1.6 kb
amplicon obtained in the A line was cloned into pNZY28 vector, using
the NZY-blunt PCR cloning kit (Nzytech) following manufacturer's in-
structions. The sequence of the resulting clone was determined in the
Sequencing Unit of Parque Cientíﬁco de Madrid.
2.9. RT-qPCR gene expression
Total RNA was extracted from the indicated L. donovani lines during
the early log phase of growth using the RNeasy Plus Mini Kit (Qiagen).
Total RNA (400 ng) was retrotranscribed to cDNA with the qScript
cDNA Synthesis Kit (Quanta Biosciences, Inc) following the manufac-
turer's instructions. The lack of genomic DNA contamination was
checked by PCR ampliﬁcation of RNA samples without prior cDNA
synthesis. The speciﬁc primer pairs, designed by using the Primer3
software (Untergasser et al., 2007) and used to amplify cDNA, were:
5′-GTGGCAGTGG TGAAAGTGTG-3′ and 5′-TCGAAGTTCA TGCTGGT
GAG-3′ for D-LDH, 5′-AGCGCCCGTA CTACATGTCT-3′ and 5′-CGATA
CGCAA TCATGCTCAC-3′ for BCAT, 5′CCACACAACA ACTCCAATGA
TG-3′ and 5′-CACAGATGGA CGGAGAGGAG-3′ for PAD, 5′-CATGAGC
TTA GCCGACAACA-3′ and 5′-GCACCACTCG TACAGGACAA AG-3′ for
SMT and 5′-TTCTCGGCTT CACCAACGAC-3′ and 5′-CCATGTAGCG
CACCAGGTC-3′ for GAPDH. Standard curves for each primer pair were
generated with 10-fold serial dilutions of L. donovani genomic DNA to
determine primer eﬃciency. Quantitative PCR was performed in a
CFX96 cycler (BioRad); each 10 μl reaction were set up containing 5 μl
of PerfeCta SYBR Green SuperMix (Quanta Biosciences), 500 nM of
each primer and 2 μl of a 1:5 dilution of the synthetized cDNA. All re-
actions were performed in duplicate and the speciﬁcity of the ampliﬁ-
cation was veriﬁed by melting curve analysis. Gene expression data
were normalized to the expression of the reference gene GAPDH, and
relative to the control sample, using the CFX Manager software with
ΔΔCt method (Livak and Schmittgen, 2001; Pfaﬄ, 2001).
2.10. Drug susceptibility in promastigotes and intracellular amastigotes of
Leishmania lines
The susceptibility of Leishmania promastigotes to SbIII, AmB, PMM,
geneticin, and nourseothricin was determined using the MTT colori-
metric assay, after incubation for 72 h at 28 °C in the presence of in-
creasing concentrations of the drug, as described previously (Kennedy
et al., 2001). In this way, it was determined the 50% eﬀective con-
centration (EC50), which is the concentration of drug that decreases the
rate of cell growth by 50%, whereas the resistance index (RI) was cal-
culated by dividing the EC50 for each resistant line or lines
overexpressing D-LDH, BCAT, PAD or SMT, by that for the corre-
sponding Leishmania control line (WT for A, P and S lines, and
WT + Lexsy or A + Lexsy for the transfected lines).
To determine the susceptibility of intracellular Leishmania amasti-
gotes to PMM, macrophage-diﬀerentiated-THP-1 cells were used. THP-
1 cells were plated at a density of 3× 105 macrophages/well in RPMI
1640 medium supplemented with 10% HIFBS, 2mM glutamate, peni-
cillin (100 U/ml), and streptomycin (100mg/ml) in 24-well tissue
culture chamber slides and, diﬀerentiated to macrophages with 20 ng/
ml of PMA treatment for 48 h followed by 24 h of culture in fresh
medium (Gomez-Perez et al., 2014). Late-stage promastigotes from L.
donovani lines were used to infect macrophages at a macrophage/
parasite ratio of 1:10. Twenty-four h after infection at 35 °C and 5%
CO2, extracellular parasites were removed by washing with phosphate
buﬀered saline (PBS; 1.2 mM KH2PO4, 8.1mM Na2HPO4, 130mM NaCl,
and 2.6mM KCl, pH 7). Infected macrophage cultures were maintained
in RPMI 1640 medium plus 10% HIFBS at 37 °C with 5% CO2 at dif-
ferent PMM concentrations for 72 h. Afterwards, macrophages were
ﬁxed for 30min at 4 °C with 2.5% paraformaldehyde in PBS and per-
meabilized with 0.1% Triton X-100 in PBS for 30min. Intracellular
parasites were detected by nuclear staining with Prolong Gold antifade
reagent plus DAPI (Invitrogen). Drug activity was determined from the
percentage of infected cells and the number of amastigotes per cell in
drug-treated versus non-treated cultures (Seifert et al., 2007).
2.11. Measurement of mitochondrial membrane potential (ΔΨm) in
Leishmania lines
ΔΨm was measured by ﬂow cytometry using Rh123 accumulation
as described previously (Garcia-Hernandez et al., 2012). Depolarization
of ΔΨm is indicated by a reduced accumulation of the dye. Parasites
(107 promastigotes/ml) were washed twice with PBS and incubated in
HBS buﬀer (21mM HEPES, 0.7mM Na2HPO4, 137mM NaCl, 5 mM KCl,
and 6mM glucose, pH 7) with 0.5 μM Rh123 for 15min at 28 °C. Then
they were washed twice with PBS, resuspended in PBS, and analyzed by
ﬂow cytometry in a FACScan ﬂow cytometer (Becton-Dickinson, San
Jose, CA) equipped with an argon laser operating at 488 nm. Fluores-
cence emission between 515 and 545 nm was quantiﬁed using the Cell
Quest software.
2.12. Measurement of reactive oxygen species (ROS) production
The generation of intracellular ROS was measured using the cell-
permeable nonﬂuorescent probes dichlorodihydroﬂuorescein diacetate
(H2DCFDA) and MitoSOX red, as described previously (Berg et al.,
2015). Brieﬂy, parasites (107/ml) of the diﬀerent L. donovani HU3 lines
were washed twice with PBS, and either directly analyzed (control
untreated) or further incubated in PBS for 2 h at 28 °C (nutritional
stress) before analyzing. Next, the promastigotes were incubated in the
same buﬀer supplemented with 4 μM H2DCFDA or 5 μM of MitoSOX for
30min at 28 °C. The ﬂuorescent dichloroﬂuorescein (DCF) product
obtained after esterase cleavage and oxidation was measured by ﬂow
cytometry using a FACScan ﬂow cytometer (Becton-Dickinson, San
Jose).
2.13. Statistical analysis
Statistical comparisons between groups were performed using
Student's t-test. Diﬀerences were considered signiﬁcant at a level of
p < 0.05. Also, when it cannot be assumed that data followed a normal
distribution, the non-parametric Wilcoxon–Mann–Whitney test was
used. A value of p < 0.05 was considered statistically signiﬁcant.
2.14. Accession numbers
RNA and DNA sequencing data have been deposited in the European
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Nucleotide Archive with the accession number PRJEB20187.
3. Results and discussion
3.1. Experimental design, global transcriptomics changes and chromosomal
alterations
In a previous work using a step-wise adaptation process (Garcia-
Hernandez et al., 2012), we established lines derived from L. donovani
(HU3 strain) with increased resistance to the four clinically relevant
antileishmanial drugs for VL: SbIII, AmB, MIL and PMM. Since the es-
tablishment of the diﬀerent lines (Garcia-Hernandez et al., 2012), they
were stored in cryobanks. For this study, the lines were thawed and
grown in the presence of the appropriate drug concentrations during 30
passages before proceeding with nucleic acids extraction. For each
passage, promastigote cultures were diluted in fresh medium at 1×106
parasites/ml and grown for 4 days until the cultures arose the sta-
tionary phase (cell density: 3-3.5× 107 parasites/ml). The concentra-
tions of drugs used during culturing of the resistant lines were: 80 μM
SbIII (line S), 0.1 μM AmB (line A), 8 μM MIL (line M) and 20 μM PMM
(line P). All resistant lines present a similar growth curves to the par-
ental strain HU3 (WT), supporting that drug pressure was not aﬀecting
the viability of parasites (Garcia-Hernandez et al., 2012).
Three independent biological replicates of each resistant line and
the WT strain, each originating from a separate growth, were processed
for RNA and DNA isolation. Illumina RNA-Seq data were independently
obtained for the poly-A+ enriched RNA fractions derived from each
one of the three replicates. In-depth genomic DNA sequencing was
carried out for replicate one from WT strain and the four resistant lines
(A, M, P and S). Table 1 shows the sequence reads that were produced
across the 20 samples, and the percentages of reads mapped to the
reference genomes for L. donovani and L. infantum. In all samples, it was
found a slightly larger number of reads mapping to the L. infantum
(JPCM5) reference genome than to the L. donovani (BPK) genome.
These results are not surprising given that L. infantum and L. donovani
species have diverged very recently and are genetically almost indis-
tinguishable (Lukes et al., 2007). Moreover, even though both reference
genomes are not complete, the L. infantum reference genome (Peacock
et al., 2007) is currently more complete than the L. donovani BPK
reference genome (Downing et al., 2011), and therefore a larger
number of reads mapped to the L. infantum reference genome. Ad-
ditionally, the transcriptome of L. infantum has been delineated (version
1; http://leish-esp.cbm.uam.es/l_infantum_downloads.html). Hence,
we decided to use the L. infantum JPCM5 genome as the reference for
the subsequent analyses.
RNA-Seq reads mapping to the L. infantum reference genome were
assigned to L. infantum transcripts and quantiﬁed using HTseq (0.6.1
(Anders et al., 2015);) and the data analyzed by DESeq2 (Love et al.,
2014) as detailed in Methods section. Transcripts showing a q-
value< 0.01 and FC diﬀerences higher than 1.5 regarding the WT line
were categorized as diﬀerentially expressed for each one of the drug-
resistant lines (S, A, M and P). A total of 1006 diﬀerentially expressed
transcripts were identiﬁed in the S line, 379 in the A line, 146 in the M
line, and 129 in the P line. A detailed list of the transcripts diﬀerentially
expressed in each one of the resistant lines is provided in the
Supplementary File 1. When the FC diﬀerences between the resistant
lines and the reference strain is ﬁxed as 2 or above (Fig. 1), the numbers
of diﬀerentially expressed transcripts decrease substantially: 194 in the
S line, 68 in the A line, 18 in the M line and 13 in the P line. Most
diﬀerentially expressed transcripts corresponded to transcript upregu-
lated in the resistant lines regarding the WT line. Venn diagrams with
the numbers of transcripts having signiﬁcantly altered levels (either up-
or down-regulated) showed the existence of a remarkable number of
concurring transcripts when the A and S lines are compared, particu-
larly among the up-regulated transcripts: 38 out of the 64 transcripts
up-regulated in the A line were found up-regulated also in the S line.
However, as discussed below, many of coincidental data might be de-
rived from somy changes for particular chromosomes observed in these
resistant lines regarding the parental strain. In fact, when Euclidean
distance heatmap analyses were used to visualize the relationship be-
tween samples based on the relative expression of all the transcripts
(Fig. 1B), a clear separation among the diﬀerent lines was observed; in
particular, the lines S and A are clearly separated.
On the other hand, we used alignments of Illumina genomic reads
against the reference L. infantum genome to assess diﬀerences in chro-
mosomal copy number among the diﬀerent resistant lines and the WT
strain (Fig. 2). After normalization, taking into account the total
number of reads obtained for each line (see Materials and Methods for
further details), the median read depth (coverage) of the chromosomal
set for each line was considered as the diploid status (solid line in
Fig. 2). In all cases (WT and resistant lines), chromosome 31 showed the
greatest reads coverage, and the data suggested that this chromosome
would be pentasomic in all samples here studied. It has been reported
previously that this chromosome is at least tetrasomic in L. major
(Akopyants et al., 2009) and other Leishmania species (Imamura et al.,
2016). Furthermore, chromosome copy number variations compared to
the WT somy were observed in the diﬀerent resistant lines. Thus, in the
S line, two extra copies for the chromosomes 1 and an extra copy for
chromosome 29 were observed, whereas the somy of chromosome 23
decreased from three (WT) to two (or lover) in the S line (Fig. 2A–B). In
the A line, the copy number of chromosome 29 was found to be one-fold
higher than that in the WT strain (Fig. 2C). In the M line, the chro-
mosome 5 achieved the status of pentasomic, even though this chro-
mosome is at least trisomic in the WT strain (Fig. 2D). Finally, in the P
line the somy for chromosomes 5 and 8 was found to be one-fold higher
than in the WT strain (Fig. 2E). With the exception of chromosome 29,
whose ampliﬁcation was found to be partial (see below), the ampliﬁ-
cation of the other chromosomes seemed to be total as the read depth
coverage was even along the whole molecules.
3.2. Diﬀerentially expressed transcripts in the L. donovani S line
Given the wide use of antimonials for leishmaniasis treatment, great
eﬀorts are being done in order to understand their damaging eﬀects on
the parasites and the underlying mechanisms of resistance developed by
Table 1
DNA- and RNA-seq data and mapping summary.
Sample Number of readsa Aligned vs LdBPKb Aligned vs LinJPCb
RNA_HU3_wt_1 18,658,148 94.97 95.92
RNA_HU3_A_1 23,474,747 94.89 95.94
RNA_HU3_M_1 15,473,695 94.87 95.79
RNA_HU3_P_1 19,785,684 94.87 95.84
RNA_HU3_S_1 18,837,447 95.12 96.14
RNA_HU3_wt_2 18,573,421 94.90 95.86
RNA_HU3_A_2 16,205,678 94.38 95.39
RNA_HU3_M_2 18,979,494 94.93 95.86
RNA_HU3_P_2 19,885,687 94.96 95.91
RNA_HU3_S_2 17,406,090 94.77 95.76
RNA_HU3_wt_3 19,274,987 95.22 96.18
RNA_HU3_A_3 18,511,557 94.94 95.97
RNA_HU3_M_3 19,042,397 95.11 96.03
RNA_HU3_P_3 21,501,077 94.91 95.87
RNA_HU3_S_3 19,868,776 95.12 96.12
DNA_HU3_wt_1 16,980,871 66.70 68.92
DNA_HU3_A_1 15,550,019 58.82 61.05
DNA_HU3_M_1 13,465,664 61.04 63.37
DNA_HU3_P_1 13,562,485 60.76 62.87
DNA_HU3_S_1 13,026,200 68.89 71.29
a The size of reads were: 2× 76 bp for RNA samples and 2× 101 bp for DNA
ones.
b Reference genomes for L. donovani (strain BPK282A1) and L. infantum
(strain JPCM5) were retrieved from TriTrypDB database (www.tritrypdb.org,
release 9.0).
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Leishmania. Results support the existence of many cellular targets for
these drugs, and a variety of mechanisms of resistance. Thus, several
metabolic pathways and membrane transporters have been implicated
in the resistance phenotype to antimonials (Laﬃtte et al., 2016b). In
agreement with this broad spectrum of responses elicited by this drug,
our study showed a tremendous alteration at the transcriptomic level in
the S line. Thus, the levels of 194 transcripts were found to be sig-
niﬁcantly altered (with FC higher than 2) in the resistant line regarding
the parental L. donovani HU3 strain (Fig. 1). Nevertheless, it is likely
that a fraction of these changes are the result of the chromosomal al-
terations observed in the resistant line (Fig. 2).
Active eﬄux of the drug has been suggested as a resistance me-
chanism to antimonials (Dey et al., 1994). In this regards, it is note-
worthy the up-regulation in the S line of two transcripts (LinJ.31.T3190
and LinJ.28.T2050) that are annotated as coding for putative trans-
porters for iron/zinc and zinc, respectively (Table 2). Another up-
regulated transcript coding also for a transporter was LinJ.06.T1320,
which encodes for a pteridine transporter.
In addition to those transcripts shown in Table 2, there are other
diﬀerentially expressed transcripts that match with data found in pre-
vious reports, reinforcing their possible association with resistance to
antimonials. Thus, Singh and co-workers demonstrated that over-ex-
pression of histone H2A increases resistance of L. donovani parasites to
sodium antimony gluconate (SAG) (Singh et al., 2010). In agreement
with that ﬁnding, we found that one of the H2A-coding transcripts (i.e.
LinJ.29.T1870) showed a 2-fold over-expression in the S line. Also, the
Salotra's group showed that over-expression of PSA-2 in L. donovani
results in development of resistance to SAG (Bhandari et al., 2013). In
agreement, we found that four transcripts coding for PSA-2
(LinJ.12.T0662, LinJ.12.T0665, LinJ.12.T0666, LinJ.12.T0690) were
about 2-fold more abundant in the resistant line (see Supplementary
File1). Gamma-glutamylcysteine synthetase (γGCS, encoded by gene
GSH1) is the rate-limiting enzyme in the biosynthesis of thiols glu-
tathione and trypanothione in Leishmania, and these thiols are con-
sidered to have a critical role in neutralizing the oxidative stress in-
duced by antimonials. In fact, overexpression of the gene GSH1 in
Leishmania leads to an increased resistance to arsenite (Grondin et al.,
1997). Conversely, Leishmania heterozygous mutants, having only one
GSH1-allele, synthesized less glutathione and trypanothione, and con-
sequently showed a signiﬁcant decreased survival in the presence of SbV
compared with control cells (Mukherjee et al., 2009). In a recent article,
it was shown that L. guyanensis parasites overexpressing GSH1 pre-
sented an increase of 4-fold in SbIII-resistance index when compared
with the wild-type line (Fonseca et al., 2017). Interestingly, our data
showed that transcript LinJ.18.T1660 (encoding for γGCS) was about
2.5-fold more abundant in the resistant S line than in the WT parasites.
Fig. 1. General analysis of diﬀerentially expressed transcripts in the amphotericin B (A), miltefosine (M), paromomycin (P) and antimonial (S) lines. A)
Venn diagram showing transcripts down- and up-regulated more than 2-fold in the resistant lines regarding the expression levels found in the parental WT line. The
Venn diagram was constructed using the online software Venn diagrams, available at Web site of the Bioinformatics and Evolutionary Genomics group of the
University of Gent and the VIB institute (http://bioinformatics.psb.ugent.be/webtools/Venn/). B) Heatmap of a hierarchical clustering analysis based on the data
from three individual replicates. Euclidean distances were calculated over rlog transformed counts using DESeq2 and plotted with pHeatmap R package (https://cran.
r-project.org). C) Volcano plots build using DESeq2 results. Dots in red represent diﬀerentially expressed genes with abs(log2(FC)) > 1 and adjusted p-value (Q
value) < 0.01. To avoid calculation errors, we have assigned the minimum adjusted p-value higher than 0 to those transcripts with adjusted p-value equal to 0. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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Furthermore, other transcripts encoding enzymes that are part of the
biosynthesis pathway of trypanothione were found to be signiﬁcantly
up-regulated in the resistant line: (i) LinJ.30.T3580, which codes for the
S-adenosylmethionine synthetase (METK2), was 1.8-fold more abun-
dant in the S line; (ii) transcript LinJ.31.T0010, encoding for a me-
thionine synthase, was 4.8-fold over-expressed in line S; (iii) transcript
LinJ.06.T0890 (dihydrofolate reductase-thymidylate synthase, DHFR-
TS) was 2.7-fold more abundant also in the S line; and (iv) transcript
LinJ.36.T6670 (methylenetetrahydrofolate reductase) that showed a
4.9-fold increased level in the S line. Together, these data support the
idea that resistance to antimonials may be linked to a general anti-
oxidant response in the parasite. In this regards, there are several
studies relating metacyclogenesis (diﬀerentiation process essential for
infectivity) to antimony resistance. Thus, in L. donovani, it was estab-
lished that the capacity of diﬀerentiation to metacyclic forms was sig-
niﬁcantly higher in antimony-resistant cells (Ouakad et al., 2011).
Another work has documented that clinical isolates showing resistance
to antimonials attained stationary phase at a higher parasite density,
contained a higher amount of metacyclic parasites and had a greater
capacity to cause in vivo infection in mice compared to the antimonial-
sensitive strains (Vanaerschot et al., 2010). Furthermore, it was found
that antimonial-resistant parasites cause a signiﬁcant higher in vivo
parasite load compared to antimonial-sensitive parasites (Vanaerschot
et al., 2011).
Fig. 2. Chromosome copy number variation in L. donovani parental line (WT) and the S, A, M and P resistant lines. The somy estimation was done using a 2-
loop method (Mondelaers et al., 2016). The median coverage of the genome is shown by a solid line, and it was assigned as 2, taking into account that diploid is
considered the major ploidy status in Leishmania. The dotted lines indicated the estimated values for other somies. Graphs were generated from the median coverage
values by barplot function of R package (https://cran.r-project.org).
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Among the top diﬀerentially expressed transcripts, it is remarkable
the presence of 5 up-regulated transcripts in the S line encoding for
members of the amastin family (LinJ.29.T1450, LinJ.29.T3000,
LinJ.29.T3010, LinJ.29.T3030, and LinJ.34.T1150). Transcripts en-
coding amastins were also found to be upregulated in the A and P lines
(see below).
On the other hand, among the 30 transcripts showing highest dif-
ferences in their steady-state levels between the parental and S lines
(Table 2), only four were down-regulated in the resistant line. Three of
them (LinJ.35.T2640, LinJ.36.T5110 and LinJ.36.T5100) encode for
hypothetical proteins without putative function, and the fourth
(LinJ.01.T0850) is annotated as coding for a metallopeptidase. Never-
theless, according to the GeneDB annotation, the latter may be a
pseudogenic transcript. However, it is curious that the levels of this
transcript (LinJ.01.T0850) remained 2.8-fold below that found in the
WT strain, despite the mutant S line has two-fold more copies of
chromosome 1 than the WT strain (Fig. 2B).
The transcript showing the greatest diﬀerence in expression was
LinJ.13.T1430, whose steady-state level was found to be 17.3-fold
higher in the resistant S line than in the parental HU3 strain. The cor-
responding gene is annotated in the GeneDB database as “protein as-
sociated with diﬀerentiation” (PAD), because its sequence conservation
with PAD1 from T. brucei. This protein, a member of the carboxylate-
transporter family, was found to be speciﬁcally expressed on the surface
of the transmission-competent ‘stumpy-form’ parasites in the blood-
stream as a prerequisite to initiate life-cycle development when trans-
mitted to their tsetse ﬂy vector (Dean et al., 2009). However, to our
knowledge, the function of this protein in Leishmania was not yet ex-
perimentally explored.
In order to conﬁrm the results obtained by RNA-Seq, the expression
of the PAD gene in the S-resistant line was analyzed. For this purpose,
total RNA from WT and S-resistant lines was extracted and the levels of
expression of PAD gene were determined by RT-qPCR; this analysis
showed that the PAD gene was expressed 2.1-fold higher in the S-re-
sistant line than in the WT line (Fig. 3A). It was unexpected to ﬁnd these
diﬀerences in the magnitude of the fold change determined for this
gene between the RNA-Seq and RT-qPCR methodologies. Finally, we
Table 2
Top 30 diﬀerentially expressed transcripts in the L. donovani line resistant to
trivalent antimony (S line).
Transcript Log2FC
(WT/A)
Producta
LinJ.35.T2640 1.65 hypothetical protein (ubiquitin supergroup?)
LinJ.36.T5110 1.62 hypothetical protein, conserved
LinJ.36.T5100 1.53 hypothetical protein, conserved
LinJ.01.T0850 1.48 peptidyl dipeptidase (pseudogenic transcript)
LinJ.29.T3030 −1.38 amastin, putative
LinJ.34.T1150 −1.38 amastin-like surface protein, putative
LinJ.36.T4910 −1.40 cytochrome b5 1, putative
LinJ.29.T2010 −1.41 hypothetical protein, conserved
LinJ.06.T0890 −1.42 dihydrofolate reductase-thymidylate synthase
(DHFR-TS)
LinJ.29.T2020 −1.43 hypothetical protein, conserved
LinJ.31.T3190 −1.45 iron/zinc transporter protein-like protein
LinJ.10.T0590 −1.47 hypothetical protein
LinJ.29.T1020 −1.53 A-1 protein, putative
LinJ.30.T2590 −1.55 formate–tetrahydrofolate ligase (FTHS)
LinJ.18.T0430 −1.61 hypothetical protein
LinJ.26.T2600 −1.62 protein kinase, putative
LinJ.29.T1450 −1.62 amastin-like protein
LinJ.29.T1210 −1.79 hypothetical protein, conserved
LinJ.06.T1320 −1.87 pteridine transporter, putative
LinJ.07.T1320 −1.88 peptide methionine sulfoxide reductase-like,
putative
LinJ.29.T1610 −1.95 hypothetical protein, conserved
LinJ.31.T0340 −1.97 hypothetical protein, conserved
LinJ.14.T0470 −1.99 cystathionine beta-lyase-like protein
LinJ.29.T3000 −2.02 amastin, putative
LinJ.31.T0010 −2.27 5-methyltetrahydropteroyltriglutamate-
homocysteine S-methyltransferase, putative
LinJ.36.T6670 −2.29 methylenetetrahydrofolate reductase, putative
LinJ.29.T3010 −2.34 amastin, putative
LinJ.29.T0930 −2.40 hypothetical protein, conserved
LinJ.28.T2050 −2.50 zinc transporter, putative
LinJ.13.T1430 −4.11 Protein Associated with Diﬀerentiation, putative
a Hypothetical protein: predicted bioinformatically; conserved: predicted
protein presents also in Trypanosoma brucei and/or T. cruzi (GeneDB).
Fig. 3. Gene expression analysis of PAD, SMT, D-LDH, and BCAT genes in diﬀerent L. donovani lines. Total RNA of L. donovani WT line, S, A and P resistant
lines, and WT + Lexsy, A + Lexsy, WT + PAD, A + SMT, WT + D-LDH, WT + BCAT, WT + D-LDH + BCAT and WT + BCAT + D-LDH transfected lines, was
extracted from promastigotes grown at log-phase as described in Materials and Methods. RT-qPCR expression values of the genes in each line were normalized with
the expression of GAPDH. The relative expression of each gene was calculated as the fold-change between the resistant lines and the WT line (which was set to 1.0)
(A) or transfected lines with PAD, SMT or D-LDH, BCAT, and WT + Lexsy, WT + Lexsy + pIR1SAT or A + Lexsy (set to 1.0) (B), see Material and Methods for
further details. Results shown are the means ± SD from two independent experiments. In all cases, signiﬁcant diﬀerences versus the controls were determined using
Student's t-test (p < 0.01).
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found the explanation in the fact that the L. infantum genome contains
two additional genes coding for PAD (LinJ.11.0660 and LinJ.11.0670)
apart from LinJ.13.1430. All three genes are conserved in the coding
regions but are divergent at their 3′UTRs. The RT-qPCR was done using
oligonucleotides derived from the coding region (common to all three
genes), whereas RNA-Seq reads are assigned to the individual tran-
scripts. In the S line, only transcript LinJ.13.T1430 is diﬀerentially
expressed.
On the other hand, to directly analyze the possible contribution of
this protein to the phenotype of antimony resistance, the PAD gene was
cloned into pLEXSY-hyg2 expression vector and transfected into the WT
line (WT + PAD line). As control, the WT line was transfected with the
empty vector, creating the WT + Lexsy line. The over-expression of the
corresponding transcripts in both transfected lines was determined by
RT-qPCR, the results showed an increase in PAD expression levels of
18.8-fold regarding the control WT + Lexsy line (Fig. 3B). In parallel,
drug susceptibility of WT, S-resistant, WT + PAD, and WT + Lexsy
lines to SbIII was determined in L. donovani promastigotes (Table 3). The
resistance index (RI) of the WT + PAD line was found to be only 1.5,
signiﬁcantly lower than the 3.7 RI value obtained for the S-resistant line
(Table 3), suggesting that the PAD protein would be contributing
slightly to the resistance phenotype in this resistant S line.
3.3. Identiﬁcation of transcripts diﬀerentially expressed in the AmB
resistant line (A line)
In the A line, among the diﬀerentially expressed transcripts re-
garding the parental line, 379 transcripts showed diﬀerences in the
expression levels above 1.5-fold (supplementary ﬁle 1), and for 68 of
them the FC was higher than 2 (Fig. 1). The top 24 down- and upre-
gulated transcripts are shown in Table 4. Most of them, 20 out of the 24,
correspond to transcripts whose levels were increased in the A line.
Another striking ﬁnding was that 19 of them correspond to the ex-
pression of genes located at chromosome 29. Moreover, when all the
diﬀerentially expressed transcripts are considered, 271 out of the 379
transcripts (71.5%) showing diﬀerential expression in the A line derive
from loci located at chromosome 29. It is likely that this enrichment in
transcripts derived from chromosome 29 is related to the fact that the
ploidy of this chromosome in the A line was found to be two-fold higher
than of the parental line (Fig. 2C). In particular, as shown in Fig. 4, the
ampliﬁcation observed in the A line aﬀected to 2/3 of the chromosome
29, from position 341113 to the end of the chromosome. Remarkably,
as shown also in Fig. 4, similar ampliﬁcation of this large region of
chromosome 29 was also observed in S line and in a lower extent in the
Table 3
Drug susceptibility in the diﬀerent L. donovani lines used in this study.
Lines SbIII EC50 μM (RI)a AmB EC50 μM (RI) PMM EC50 μM (RI)
WT 89.12 ± 9.67b 0.09 ± 0.01 14.14 ± 2.36
S 331.21 ± 39.08
(3.72)
-c –
A – 0.23 ± 0.04
(2.64)
–
P – – 132.37 ± 8.26
(9.36)
WT + Lexsy 79.62 ± 12.56 – 11.98 ± 0.63
A + Lexsy – 0.31 ± 0.02
(3.56)
–
WT + PAD 117.96 ± 14.11
(1.48)
– –
A + SMT – 0.12 ± 0.03
(1.35)
–
WT + D-LDH – – 58.36 ± 3.07
(4.87)
WT + BCAT – – 48.94 ± 4.52
(4.08)
WT + Lexsy + pIRSAT – – 13.92 ± 2.36
WT + D-LDH + BCAT – – 56.76 ± 6.25
(4.08)
WT + BCAT + D-LDH – – 66.24 ± 3.39
(4.76)
a Resistance indexes (RI) were calculated by dividing the EC50 for each resistant line, or overexpressing D-LDH, BCAT, PAD or SMT lines, by that for
Leishmania control line (WT for A, P and S lines, WT + Lexsy or A + Lexsy for the transfected lines, and WT + Lexsy + pIRSAT for cotransfected lines).
b Data are the averages ± SD of EC50 values from six independent experiments. Signiﬁcant diﬀerences versus the controls were determined using
Student's t-test (p < 0.005).
c -: Not determined.
Table 4
Top 24 diﬀerentially expressed transcripts in the L. donovani AmB resistant line
(A line).
Transcript Log2FC (WT/A) Product
LinJ.36.T2510 2.86 sterol 24-c- methyltransferase, putative
LinJ.36.T5110 1.26 hypothetical protein, conserved
LinJ.36.T5100 1.21 hypothetical protein, conserved
LinJ.23.T0700 1.13 hypothetical protein
LinJ.29.T1260 −1.12 hypothetical protein, conserved
LinJ.29.T1550 −1.13 phosphatidylinositol 4- kinase alpha, putative
LinJ.29.T1090 −1.14 hypothetical protein, conserved
LinJ.29.T2820 −1.14 hypothetical protein, conserved
LinJ.29.T1460 −1.15 RNA binding protein, putative
LinJ.29.T1880 −1.15 paraﬂagellar rod protein 1D, putative
LinJ.29.T2950 −1.15 hypothetical protein, conserved
LinJ.29.T2400 −1.16 hypothetical protein
LinJ.26.T2600 −1.17 protein kinase, putative
LinJ.29.T1600 −1.17 hypothetical protein, conserved
LinJ.29.T1020 −1.19 A-1 protein, putative
LinJ.29.T1630 −1.19 hypothetical protein, conserved
LinJ.29.T1890 −1.21 paraﬂagellar rod protein 1D, putative
LinJ.29.T3030 −1.27 amastin, putative
LinJ.29.T2010 −1.30 hypothetical protein, conserved
LinJ.29.T1210 −1.39 hypothetical protein, conserved
LinJ.29.T1450 −1.41 amastin-like protein
LinJ.29.T1610 −1.50 hypothetical protein, conserved
LinJ.29.T3000 −1.77 amastin, putative
LinJ.29.T3010 −2.07 amastin, putative
a Hypothetical protein: predicted bioinformatically; conserved: predicted pro-
tein presents also in Trypanosoma brucei and/or T. cruzi (GeneDB).
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P line. In all three cases, an abrupt change in coverage was mapped in
the divergent strand switch region (dSSR) located between genes
LinJ.29.0960 and LinJ.29.0970. At present, the molecular mechanism
responsible for this partial ampliﬁcation of this chromosome could not
be depicted; the SIDER2 repeated sequences found in the vicinity
(Fig. 4B) did not seem to be involved in the rearrangement. However,
we found in this dSSR several sequences with potential to conform G-
quadruplexes, and given the constraints that these structures impose in
DNA replication (Valton and Prioleau, 2016), they may be chromo-
somal fragile sites. This would explain that the same chromosomal al-
teration is observed in the three resistant lines (A, S and P; Fig. 4B).
The highest FC between the AmB resistant line and the parental
strain corresponded to the transcript LinJ.36.T2510 (Table 4), which is
about 7-fold more abundant in WT strain than in the resistant A line.
This transcript codes for 24-sterol methyltranferase (SMT), an enzyme
that methenylates steroids at the 24 position during ergosterol bio-
synthesis. Studies in L. major has shown that this enzyme is mainly
localized in the endoplasmic reticulum (Jimenez-Jimenez et al., 2008).
The postulated mode of action for AmB suggests that the compound
forms complexes with 24-substituted sterols, such as ergosterol in the
cell membrane, and then causes pores which alter ion balance and re-
sult in cell death (Croft and Coombs, 2003). Hence, taking into account
the speciﬁc interaction between AmB and ergosterol, a decrease in the
activity of the enzyme SMT in the A line would be a plausible resistance
strategy to elude the toxicity of this polyene antimycotic. Interestingly,
in a previous work dealing with the mechanism of AmB resistance in L.
donovani promastigotes, it was found that the major sterol present in
the membrane of resistant parasites was an ergosterol precursor, the
cholesta-5, 7, 24-trien-3b-ol and not ergosterol, which is the most
abundant sterol present in the membrane of the AmB-sensitive strain;
therefore, it was concluded that this AmB-resistant Leishmania was
defective in C-24 transmethylation of C-27 sterols (Mbongo et al.,
1998).
Analysis by whole genome sequencing of the locus Ld-SMT in the
WT strain and in the A line showed a sharp decrease in coverage in the
A line, suggesting a possible gene deletion event in the A resistant line
(Fig. 5A). In the genome of L. infantum, and other Leishmania species,
there are two tandemly organized genes (LinJ.36.2510 and
LinJ.36.2520) showing an absolute sequence identity in their coding
regions, but diﬀerent in their untranslated regions. Additional experi-
mental evidence of a deletion event occurring in the A line was ob-
tained after PCR ampliﬁcation of the locus using two oligonucleotides
designed to amplify the genomic region containing genes LinJ.36.2510
and LinJ.36.2520. As shown in Fig. 5B, an ampliﬁcation product of
approx. 1.6-kb long was obtained from genomic DNA of the A line, but
no when using genomic DNA of the parental strain as template. In
contrast, a slight ampliﬁcation band around 5.5-kb was observed only
in the PCR from WT DNA. The latter is the expected size for the am-
pliﬁcation product of the complete region according to the L. infantum
JPCM5 reference genome. After direct sequencing of the 1.6-kb am-
pliﬁcation product, speciﬁc for the A line, it was conﬁrmed that a de-
letion event took place in the resistant line leading to the loss of one
SMT gene and the intercoding region separating the orthologues to
genes LinJ.36.2510 and LinJ.36.2520. Arguably, this deletion was the
result of an intrachromosomal homologous recombination event be-
tween the coding regions of genes LinJ.36.2510 and LinJ.36.2520.
Hence, as a result, the A line would lose the LinJ.36.T2510 transcript,
and, predictably, would have a lower expression of SMT enzyme, and
the subsequent decrease of ergosterol levels at the parasite cell mem-
branes. In agreement with this hypothesis, a study by Pourshaﬁe et al.
(2004) showed the existence in L. donovani of two transcripts encoding
for SMT, named SCMT A and SCMT B; interestingly, SCMT A was found
to be absent in an AmB-resistant L. donovani line, selected by stepwise
drug pressure. More recently, an L. donovani clinical isolate obtained
from an AmB-nonresponsive patient was investigated to understand the
mechanism of AmB resistance (Purkait et al., 2012). In that study, it
was found that the transcript SCMT A was absent in AmB-resistant
parasites, but expressed in susceptible parasites.
To validate that SMT genes present altered levels of expression in
the AmB-resistant line, as deduced from the RNA-Seq data, total RNA of
WT and A lines was extracted and the relative amount of SMT tran-
scripts was analyzed by RT-qPCR. As shown in Fig. 3A, and in
Fig. 4. Read coverage along the chro-
mosome 29 in WT and A, S and P re-
sistant lines. The coverage values obtained
with genomeCoverageBed (BEDTools) were
smoothed by an in-house Perl script that
calculates the mean value within over-
lapping 5-Kb windows. Graphs were gener-
ated from the coverage values by plotly
utility of R package (https://cran.r-project.
org). Panel A shows the coverage along the
complete chromosome 29, whereas panel B
shows the region comprised between the
coordinates 322,447 and 390,000 of this
chromosome. Green-colored boxes denote
ORF (the gene names are indicated), and
red-boxes correspond to repeated sequences
of the SIDER2 family (Requena et al., 2017).
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agreement with the RNA-Seq data, the expression levels were 3.9-fold
lower in the A line than in the WT line. Next, we asked whether
overexpression of SMT in the A line might restore the susceptibility of
this line to AmB. For this purpose, the SMT gene was cloned into the
pLexsy-hyg2 expression vector, and the construct used to transfect the
AmB-resistant line, the resulting line was named A + SMT. In parallel,
as control, the AmB-resistant line was transfected with the empty
pLexsy-hyg2 vector to create the line A + Lexsy. The results obtained
by RT-qPCR showed a 75.2-fold over-expression of SMT gene in the
A + SMT line compared to the control (Fig. 3B). Finally, the suscept-
ibility to AmB of WT, A-resistant, A + SMT, and A + Lexsy transfected
lines was determined in promastigotes. As shown in Table 3, when the
A line over-expressed the SMT gene (A + SMT), it lost the resistance to
AmB, showing similar EC50 values for AmB that the WT line (0.12 and
0.09 μM, respectively). On the contrary, the control line (A + Lexsy)
maintained the resistance to AmB and exhibited EC50 values for AmB
3.6-fold higher than the WT line. Altogether, these data suggest that the
lower SMT expression in the A line respect to the WT strain is directly
related to the loss of one SMT gene. Therefore, these results support the
use of SMT as a drug resistance marker for AmB resistance. Thus, a PCR
based on the ampliﬁcation of the SMT locus (as depicted in Fig. 5B)
might be useful to quickly check SMT deletion events in AmB-resistant,
clinical isolates.
On the other hand, the ampliﬁcation of the most part of chromo-
some 29, occurring in the A line, suggests that expression of some gene
(s) located at this chromosome may be contributing to the phenotype of
resistance to AmB. However, the identiﬁcation of that/those driver
gene(s) is not a simple task, taking into account that 271 transcripts
derived from this chromosome show increased levels regarding the
expression levels in WT L. donovani HU3 (Supplementary ﬁle 1). It is
noticeable that among the most upregulated transcripts, three are an-
notated as coding for amastin (LinJ.29.T3000, LinJ.29.T3010,
LinJ.29.T3030) and an additional overexpressed transcript
(LinJ.29.T1450) is annotated as an amastin-like protein. Amastin genes
were ﬁrst described in Trypanosoma cruzi because of their speciﬁc ex-
pression at the amastigote stage of this parasite (Teixeira et al., 1994).
Subsequently, these genes were identiﬁed in Leishmania, and genomic
analysis showed that the amastin repertoire is much larger in Leish-
mania relative to Trypanosoma spp. (Rochette et al., 2005; Jackson,
2010). Thus, in the genomes of L. major and L. infantum up to 45
amastin genes were identiﬁed, comprising the largest gene family re-
ported so far in Leishmania (Rochette et al., 2005). However, it was
somewhat remarkable that none of the four genes, identiﬁed as up-
regulated in the A line, was catalogued as coding for amastin in those
previous studies. Hence, we analyzed the information regarding these
four genes in the GeneDB database. Orthologues to these four genes do
not exist in the L. major genome. These genes are highly conserved in
sequence each other; thus, the protein encoded by gene LinJ.29.3000
shares 98, 94 and 61% of sequence identity with the proteins encoded
by genes LinJ.29.1450, LinJ.29.3010 and LinJ.29.3030, respectively. In
contrast, the sequence identity between the LinJ.29.3000-encoded
protein and that encoded by gene LinJ.08.0820, a prototypical amastin-
gene (Rochette et al., 2005), is only 49%. Although the function of
amastin is unknown, its structure is typical for a membrane protein,
containing four hydrophobic transmembrane domains, interspersed
with serine–threonine rich, extracellular domains and probable glyco-
sylation sites (Teixeira et al., 1994; Rochette et al., 2005). Taking into
account a possible location of these molecules in the parasite mem-
brane, and given the interaction of AmB with ergosterol, the pre-
dominant sterol in the membrane of Leishmania (Croft et al., 2006), it
can be postulated that an increased expression of this class of amastins
may be hampering the interaction of the drug with the membrane in the
Leishmania resistant A line. Studies based on the overexpression of these
genes would serve to test this hypothesis.
Among other transcripts also showing increased levels in the A line
regarding the WT strain is LinJ.29.T1250 (see supplementary ﬁle 1),
which codes for tryparedoxin 1 (TXN1). Interestingly, in a recent study,
the protein expression levels of this antioxidant molecule was found to
be 2–3 fold higher in AmB resistant isolates as compared to sensitive
strains of L. donovani (Suman et al., 2016). Thus, our data reinforce the
hypothesis that over-expression of TXN1 might be linked to AmB re-
sistance.
3.4. Transcripts diﬀerentially expressed in a MIL resistant line (M line)
Eighteen transcripts were found to have above 2-fold expression
diﬀerences between the M line and the parental parasites (Fig. 1), and
Table 5 shows those having annotated genes. Remarkably, most of them
are transcripts that result downregulated in the M parasites. MIL re-
sistance mechanisms in Leishmania spp. are associated with a decrease
in intracellular drug accumulation due to the defective inward trans-
location of MIL (Perez-Victoria et al., 2003b, 2006b; Sanchez-Cañete
et al., 2009; Mondelaers et al., 2016) and the overexpression of a P-
glycoprotein MDR1 (ABCB4), which is responsible for drug eﬄux
(Perez-Victoria et al., 2001, 2006a). Additionally, a member of the ABC
subfamily G transporter, LiABCG4, has been found to confer moderate
(2-fold) resistance to MIL; this protein has been involved in the outward
transport of phosphatidylcholine analogues from the cytoplasmic to the
exoplasmic leaﬂet of the parasite membrane (Castanys-Muñoz et al.,
2007). More recently, a Leishmania protein of unknown function,
Fig. 5. Deletion of a SMT gene in the
AmB resistant line. (A) Read depth dis-
tribution of Illumina reads from WT and A
in the region 948,788–962,094 of chromo-
some 36. An in-house Perl script was used
for representing the smooth coverage with a
200 nucleotide-window and a normal-
ization by the total number of reads from
each sample. In the bottom, a graph
showing the ORF of the genes located in this
region is included. The ORFs of genes
LinJ.36.2510 and LinJ.36.2520 are iden-
tical and code for SMT. The location and
sizes of transcripts LinJ.36.T2510 and
LinJ.36.T2520 are indicated by arrows with
rhomboid heads. The slim arrows indicate
the position of the oligonucleotides used for
PCR ampliﬁcation of the region. (B) PCR
ampliﬁcation with oligonucleotides gSMT-Fw and gSMT-Rv using as template genomic DNA from WT strain or A line. The green arrow points to the expected
amplicon in the WT line, whereas the red one indicates the amplicon observed in the A line. HindIII-digested DNA of Φ29 phage was used as molecular weight marker
(M). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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named P299 (LinJ.08.0630), has also been linked to MIL resistance;
thus, overexpression of its gene led to a 2.6-fold increased protection
against MIL (Choudhury et al., 2008).
As LMT/LRos3 complex is pivotal for resistance towards MIL (Perez-
Victoria et al., 2003b, 2006a, 2006b), we ﬁrst looked for possible al-
terations in the steady-state levels of transcripts LinJ.13.T1590 (LMT)
and LinJ.32.T0540 (LRos3). The steady-state levels of both transcripts
were slightly higher in the WT strain than in the M line: 1.1-fold for
LinJ.13.T1590 and 1.2-fold for LinJ.32.T0540. However, these diﬀer-
ences were not found to be statistically signiﬁcant in this MIL-resistant
line.
In a recent study, the dynamics of the appearance of single nu-
cleotide polymorphisms (SNP) in the LMT gene was analyzed during the
selection process for MIL resistance in an L. infantum strain (Laﬃtte
et al., 2016a). Interestingly, it was observed an increase in mutated
alleles under high drug pressure. Additionally, in a recent report, the
existence of point mutations in the LMT gene of two MIL-resistant
clinical isolates has been documented (Srivastava et al., 2017). In our
MIL resistant line, we examined SNPs in the coding regions of genes
LMT and LRos3, comparing sequence reads derived from the WT and M
DNA samples. We identiﬁed a heterozygous SNP at position 1041 in the
LMT gene of the M line: 42% of the reads showed an A and the rest a G
residue at that position, whereas no SNP was found in the WT. Inter-
estingly, the G-to-A change leads to the appearance of a stop codon at
triplet 347, which in the WT protein codes for Trp. In conclusion, our
data suggest that the resistance to MIL in the M line may be associated
with a decreased expression of the MIL transporter, leading to a mild
alteration in the MIL-inward translocation system. It must be noted that
the resistance index of this M line to MIL is 2.5 (data not shown),
whereas L. donovani promastigotes, having a non-functional MT sub-
unit, are 15-fold more resistant to MIL than WT parasites (Perez-
Victoria et al., 2003a).
While the mechanisms of action of MIL are not yet completely un-
derstood, several studies have pointed to alterations in phospholipid
metabolism, impairment of bioenergetic metabolism, and recently to
the induction of apoptosis as potential modes of action (Paris et al.,
2004; Rakotomanga et al., 2007; Mishra and Singh, 2013). From the
diﬀerential expressed transcripts in the M line, it is not immediately
intuitive to postulate a possible role of the encoded proteins in the re-
sistance phenotype of this line. Most of the diﬀerentially expressed
transcripts appeared as down-regulated in the M line (Table 5), and
those that were found to be upregulated showed a modest 2-FC and,
furthermore, code for proteins of unknown function. Among the
downregulated transcripts, there are two transcripts, LinJ.17.T0990
and LinJ.23.T1230, which code for proteins associated with metacy-
clogenesis (META1 and SHERP, respectively). Thus, META1 has in-
creased expression at the stationary phase of L. amazonensis, L. donovani
and L. major promastigotes (Uliana et al., 1999). The other protein,
SHERP (small hydrophilic endoplasmic reticulum (ER)- associated
protein), is expressed only in metacyclics, in which it shows association
with the ER and outer mitochondrial membrane (Knuepfer et al., 2001).
Among other transcripts down-regulated in the M-line, there are
two coding for transporters: LinJ.31.T0370 (coding for the amino acid
transporter AAT1.3) and LinJ.10.T0380 (coding for a folate/biopterin
transporter). Leishmania contain a large family of folate/biopterin
transporters composed by 14 diﬀerent members, and it is remarkable
that one of them, FT1 (encoded by gene LinJ.10.0400) is not expressed
in methotrexate-resistant L. infantum (Ouameur et al., 2008). In a recent
work, Vacchina and co-workers (Vacchina et al., 2016) analyzed
changes in gene expression by RNA-Seq in a MIL-resistant line of L.
donovani, and also they found a down-regulation of several folate/
biopterin transporters in the resistant line. Additionally, coincident
with our data (supplementary ﬁle 1), these authors identiﬁed, as down-
regulated in their MIL-resistant line, the genes coding for an amino acid
permease (AAT20.2; LinJ.10.0770), a surface antigen-like protein
(LinJ.04.0170) and a hypothetical protein (LinJ.04.0160).
3.5. Transcripts diﬀerentially expressed associated with the resistance to
PMM in the P-line
The mechanism of action of PMM has been well studied in
Escherichia coli, where it binds to the 30S ribosomal A-site RNA, and
causes misreading of the genetic code and inhibits translocation
(Fourmy et al., 1996). Aminoglycosidic antibiotics were initially used
against bacterial infection (currently, they are out of clinical use), but
subsequently some were found to be eﬀective against several parasites,
among others, Leishmania (Davidson et al., 2009). However, the me-
chanism(s) of action of PMM in Leishmania spp is(are) not known yet
(Croft et al., 2006), even though recent studies point to an interaction
with the Leishmania ribosome A-site (Shalev et al., 2015). On the con-
trary, resistance to aminoglycosides in bacteria is well known and it is
attained by three ways: (i) decreased uptake; (ii) alteration of the ri-
bosomal binding site, and (iii) chemical modiﬁcation of the amino and/
or hydroxyl groups by bacterial enzymes (Davies and Wright, 1997).
In our study, only 13 transcripts varied above 2-fold in the PMM-
resistant line (P line; Fig. 1). Table 6 shows those transcripts having
annotated genes. Among them, two transcripts (LinJ.27.T1940 and
LinJ.27.T1950) were strongly up-regulated in the resistant line, 56- and
32-fold, respectively, compared to their expression in the parental (WT)
line. According to GeneDB annotations, the encoded products for these
Table 5
Protein-coding transcripts that are diﬀerentially expressed in the L. donovani
miltefosine resistant line (M line).
Transcript Log2FC (WT/
A)
Producta
LinJ.17.T0690 1.84 hypothetical protein
LinJ.26.T2600 1.75 protein kinase, putative
LinJ.14.T0180 1.58 carboxypeptidase, putative,
LinJ.31.T0370 1.41 amino acid transporter AAT1.4
LinJ.17.T0990 1.29 META1
LinJ.23.T1230 1.27 small hydrophilic endoplasmic reticulum-
associated protein (SHERP)
LinJ.32.T3810 1.21 3-hydroxyisobutyryl-coenzyme a hydrolase-like
protein
LinJ.20.T1370 1.17 kinase-like protein
LinJ.07.T0910 1.13 ﬂavoprotein subunit-like protein
LinJ.28.T1070 1.13 P27 protein (P27)
LinJ.10.T0380 1.00 folate/biopterin transporter, putative
LinJ.33.T1860 −1.06 OTT_1508-like deaminase, putative
LinJ.08.T0180 −1.19 hypothetical protein
a Hypothetical protein: predicted bioinformatically; conserved: predicted
protein presents also in Trypanosoma brucei and/or T. cruzi (GeneDB).
Table 6
Protein-coding transcripts that are diﬀerentially expressed in the L. donovani
paromomycin-resistant line (P line).
Transcript Log2FC (WT/
A)
Producta
LinJ.07.T0910 1.06 ﬂavoprotein subunit-like protein
LinJ.29.T1600 −1.00 hypothetical protein, conserved
LinJ.29.T1450 −1.06 amastin-like protein
LinJ.13.T1430 −1.07 Protein Associated with Diﬀerentiation,
putative
LinJ.29.T0930 −1.24 hypothetical protein, conserved
LinJ.31.T3190 −1.37 iron/zinc transporter protein-like protein
(LIT1)
LinJ.29.T3000 −1.79 amastin, putative
LinJ.27.T1950 −4.98 branched-chain amino acid aminotransferase,
putative
LinJ.27.T1940 −5.77 D-lactate dehydrogenase-like protein, putative
a Hypothetical protein: predicted bioinformatically; conserved: predicted
protein presents also in Trypanosoma brucei and/or T. cruzi (GeneDB).
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transcripts are D-lactate dehydrogenase-like protein (D-LDH) and an
aminotransferase of branched-chain amino acids (BCAT), respectively.
More strikingly, genomic DNA coverage revealed that the region en-
coding for both transcripts, which are collinear, was over-replicated
about 150-fold in the PMM-resistant line (Fig. 6). At present, we have
not investigated about the nature of this amplicon, whether intra- or
extra-chromosomal, but the presence of 2 direct repeats of 424-nu-
cleotides in length that are located in the intergenic region (Fig. 6B) is
noteworthy. The genome of Leishmania contains a signiﬁcant number
(around 2000) of repeated DNA sequences (Ubeda et al., 2014), which
provide to this parasite the capacity of generating chromosomal re-ar-
rangements and extrachromosomal DNA elements in response to drugs
pressure (Laﬃtte et al., 2016b).
The over-expression of the D-LDH and BCAT genes observed by
RNA-Seq in the PMM-resistant line was conﬁrmed by RT-qPCR (46.6-
and 19.2-fold of over-expression, respectively, regarding the WT strain;
Fig. 3A). In order to evaluate the possible contribution of these genes to
PMM resistance in Leishmania, we created the constructs expressing
either separately each one of the genes or co-expressing both D-LDH
and BCAT genes. As shown in Fig. 3B, a signiﬁcant increase in the ex-
pression of the genes (32.0-fold and 47.93-fold for D-LDH and BCAT,
respectively) was observed after transfection of the Leishmania WT line
with the D-LDH or BCAT-expressing constructs (lines WT + D-LDH and
WT + BCAT, respectively, Fig. 3B). Interestingly, both transfectants
acquired a signiﬁcant resistance against PMM, with RI values of 4.9 and
4.1 for WT + D-LDH- and WT + BCAT-transfected lines, respectively,
whereas the RI value of P line was 9.4 (Table 3). Nevertheless, co-ex-
pression of both D-LDH and BCAT genes in L. donovani WT line did not
produce a synergistic eﬀect, obtaining values of EC50 to PMM in the
same range of single overexpression of either D-LDH or BCAT (Table 3).
Nevertheless, we could not achieve similar expression levels to the
single overexpression of BCAT gene despite using diﬀerent plasmids
and after 13 passages with 100 μg/ml of nourseothricin or Hyg
(Fig. 3B).
To gain greater understanding on the molecular basis linking the
overexpression of D-LDH and BCAT genes to PMM resistance, we ana-
lyzed the resistance of both the P line and the transfected parasites with
D-LDH and BCAT to other aminoglycosidic antibiotics such as geneticin
(G-418) and nourseothricin. Remarkably, three independent transfec-
tion experiments indicated a signiﬁcant cross-resistance (Table 7), with
average RI values to geneticin of 5.6 and 4.5 for WT + LDH- and
WT + BCA-transfected lines, respectively, whereas the RI value for P
line was 12.1. Regarding nourseothricin, WT + D-LDH and
WT + BCAT-transfected lines exhibited average RI values of 1.9 and
2.1, respectively, whereas it was determined an RI value of 3.5 for P
line (Table 7). The similar high RI values of the P line and the trans-
fectants against PMM and geneticin might be related to the fact that
their structures are very close, whereas the structure of nourseothricin
is clearly diﬀerent. This suggested that the resistance may arise from
chemical modiﬁcation of the amino and/or hydroxyl groups of these
Fig. 6. Ampliﬁcation in the P line of the
genomic region containing the genes
LinJ.27.1940 (D-LDH) and LinJ.27.1950
(BCAT). (A) The reads coverage along a
region (coordinates 853,000–872,000) of
the chromosome 27 in both WT and P lines
is shown. The coverage values obtained
with genomeCoverageBed (BEDTools) were
smoothed by an in-house Perl script that
calculates the mean value within over-
lapping 200-nucleotide windows. Note that
a logarithmic scale is used to represent the
coverage values. (B) Schematic drawing of
the ampliﬁed genomic region, showing the
position of genes LinJ.27.1940 (D-LDH) and
LinJ.27.1950 (BCAT). The red boxes corre-
spond to two identical sequences of 424-
nucleotides in length. The dotted arrow at
the bottom denotes the transcriptional di-
rection of the genes. (For interpretation of
the references to color in this ﬁgure legend,
the reader is referred to the Web version of
this article.)
Table 7
Aminoglycosides susceptibility in L. donovani lines.
Lines PMM EC50 μM (RI)a Geneticin EC50 μg/ml (RI) Nourseothricin EC50 μg/ml (RI)
WT 12.18 ± 1.31b 0.44 ± 0.09 9.26 ± 1.52
P 122.76 ± 7.32 (10.08) 5.34 ± 0.81 (12.14) 32.81 ± 4.16 (3.54)
WT+Lexsy 13.14 ± 1.28 0.42 ± 0.09 8.13 ± 0.59
WT+D-LDH 62.15 ± 4.07 (4.73) 2.36 ± 0.23 (5.62) 15.51 ± 1.52 (1.91)
WT+BCAT 48.79 ± 4.80 (3.71) 1.88 ± 0.20 (4.48) 16.81 ± 1.77 (2.07)
a Resistance indexes (RI) were calculated by dividing the EC50 for P line, or overexpressing D-LDH or BCAT lines by that for Leishmania control line (WT for P, and
WT + Lexsy for WT + D-LDH and WT + BCAT).
b Data are the averages ± SD of EC50 values from six independent experiments for three independent transfections. Signiﬁcant diﬀerences versus the controls
were determined using Student's t-test (p < 0.001).
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antibiotics, and that the putative over-expression of enzymes D-LDH
and BCAT may be contributing to the chemical modiﬁcation of these
molecules. Nevertheless, other metabolic possibilities exist and they
were further explored (see below).
Firstly, it was analyzed if the resistance observed in promastigote
forms was also maintained in intracellular amastigotes obtained after
infection of THP-1 cells with the diﬀerent promastigote lines (Table 8).
The results showed that the resistance to PMM in intracellular amasti-
gotes was maintained; with RI values of 2.9 and 2.4 for WT + D-LDH
and WT + BCAT transfected lines, respectively, whereas the RI for P
line was 4.1 (Table 8). These values were 2.78 and 2.79 to the WT + D-
LDH + BCAT and WT + BCAT + D-LDH lines, respectively, when the
co-transfection with both D-LDH and BCAT genes were done. These
results demonstrate that the resistance phenotype to PMM in the
amastigote stage of the L. donovani P line would be due in part to the
over-expression of D-LDH and BCAT.
Additionally, we wanted to know whether over-expression of D-LDH
or BCAT genes in other Leishmania species/strains also confer resistance
to PMM. For this purpose, promastigotes of L. donovani (Dd8 strain), L.
major (Friedlin strain), and L. infantum (JPCM5 strain) were transfected
with either D-LDH- or BCAT-expressing vectors, and the over-expres-
sion of the corresponding transcripts was conﬁrmed by RT-qPCR (data
not shown). Afterwards, drug susceptibility of WT, WT + D-LDH,
WT+ BCAT, and WT+ pLexsy (transfection control) lines to PMM was
determined in both promastigote and amastigote forms of the diﬀerent
Leishmania species (Table 9). In all cases, both D-LDH- and BCAT-
transfected promastigotes of L. donovani Dd8, L. major and L. infantum
lines showed higher values of RI than the corresponding control lines
(Table 9). Also, the intracellular amastigote forms showed higher RI
values than the control lines, even though only the L. donovani Dd8
amastigotes over-expressing D-LDH or BCAT genes showed statistically
signiﬁcant diﬀerences in RI values in regard to the control ones
(Table 9). Overall, these results suggest that D-LDH and BCAT genes can
contribute to the resistance phenotype to PMM in other Leishmania
species, although apparently to a lesser extent than in L. donovani HU3,
probably due to their diﬀerent genetic background.
In addition, we analyzed the stability of resistance to PMM after
removal of the drug pressure. After 2, 3, and 4 months of culturing the P
line in absence of PMM, the EC50 values were determined. As shown in
Fig. 7A, the EC50 values signiﬁcantly decreased from the initial EC50
value of the P line (132.4 μM) to 89.2, 70.4, and 65.1 μM, after growing
the P line in absence of PMM during 2, 3 and 4 months, respectively. In
parallel, the levels of expression of D-LDH and BCAT genes were de-
termined by RT-qPCR at the same times of drug removal (Fig. 7B).
These data showed that the expression of D-LDH gene decreased to
54.9, 41.5, and 25.3% of the initial value, whereas the expression of
BCAT gene decreased to 65.9, 43.6, and 51.7%, in the P line grown 2, 3
and 4 months without drug pressure (Fig. 7B). Therefore, we can con-
clude the existence of a direct relationship between PMM resistance and
expression levels of these genes in L. donovani HU3, supporting further
the involvement of D-LDH and BCAT genes in the resistance to PMM in
Leishmania.
It is known that PMM interferes with mitochondrial activity, dis-
rupting the ΔΨm; even though it has been proposed that this drug
would be acting at a metabolic level upstream of the respiratory chain
(Maarouf et al., 1997; Jhingran et al., 2009). Our results showed that
the PMM-resistant line analyzed in this study presents a low accumu-
lation of Rh123 (Fig. 8), indicating that this line also presents a di-
minished ΔΨm, as described for other experimental PMM resistant
parasites (Jhingran et al., 2009). Considering that D-LDH and BCAT
would be involved in metabolic pathways to obtaining energy
(Opperdoes and Coombs, 2007), it was determined whether the over-
expression of either D-LDH or BCAT might aﬀect the ΔΨm by inter-
fering with metabolic processes leading to mitochondrial ATP synthesis.
As depicted in Fig. 8, no depolarization was observed in promastigotes
over-expressing D-LDH (WT + D-LDH line). However, promastigotes
that over-expressed BCAT (WT + BCAT line), similar to the PMM-re-
sistant promastigotes (P line), showed a signiﬁcant decrease in the
ΔΨm with respect to the control (WT + Lexsy line) (Fig. 8). The same
behavior was observed when promastigotes were exposed to PBS for 2 h
(Fig. 8), as an inducer of mitochondrial stress. As described, nutritional
starvation induces autophagy in Leishmania (Besteiro et al., 2006);
being autophagy required for the maintenance of mitochondrial
homeostasis (Williams et al., 2013). In conclusion, this ﬁnding would
suggest that the alteration of ΔΨm may be a consequence of a direct
interference of the BCAT activity with oxidative phosphorylation in the
Leishmania mitochondrion. Enzymes for the degradation of branched-
chain amino acids are predicted to localize into the mitochondrion
(Afanador et al., 2014). Thus, it is plausible that the aberrant
Table 8
Paromomycin susceptibility in intracellular amastigotes of L. donovani
lines.
Lines PMM EC50 μM (RI)a
WT 9.49 ± 1.21b
P 38.51 ± 3.83 (4.05)
WT + D-LDH 29.24 ± 3.26 (2.96)
WT + BCAT 24.03 ± 2.64 (2.44)
WT + Lexsy 9.86 ± 1.30
WT + D-LDH + BCAT 36.37 ± 5.81 (2.78)
WT + BCAT + D-LDH 38.47 ± 6.32 (2.94)
WT + Lexsy + pIRSAT 13.09 ± 2.61
a Resistance indexes (RI) were determined from the percentage of
infected cells and the number of amastigotes per cell in drug-treated
cultures versus non-treated cultures.
b Data are the mean ± SD of EC50 values from four independent
experiments. Signiﬁcant diﬀerences versus the controls were de-
termined using Student's t-test (p < 0.001).
Table 9
Paromomycin susceptibility of diﬀerent species of Leishmania transfected with D-LDH and BCAT.
Lines L. donovani Dd8
EC50 μM (RI)a
L. major
EC50 μM (RI)
L. infantum
EC50 μM (RI)
Promastigotes Intracellular amastigotes Promastigotes Intracellular amastigotes Promastigotes Intracellular amastigotes
WT 40.48 ± 4.09b 45.97 ± 5.97 6.60 ± 0.40 15.71 ± 1.52 40.16 ± 4.69 62.19 ± 7.88
WT+D-LDH 79.99 ± 7.20***
(1.85)
63.61 ± 7.36*
(1.53)
16.43 ± 2.01***
(2.01)
18.98 ± 2.62
(1.14)
74.87 ± 9.63***
(1.88)
76.71 ± 9.62
(1.20)
WT+BCAT 61.53 ± 2.82***
(1.43)
65.02 ± 6.11**
(1.56)
10.58 ± 0.97*
(1.31)
21.02 ± 2.27
(1.27)
56.17 ± 5.27*
(1.42)
65.19 ± 7.12
(1.02)
WT+Lexsy 43.03 ± 4.11 41.52 ± 5.15 8.10 ± 0.40 16.51 ± 1.94 39.68 ± 4.19 63.68 ± 5.23
a Resistance indexes were calculated as described in Table 3 (for promastigotes) and Table 8 (for amastigotes).
b Data are the mean ± SD of EC50 values from three independent experiments. Signiﬁcant diﬀerences versus the controls were determined using Student‘s t-test
(*p < 0.05; **p < 0.01; ***p < 0.005).
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overexpression of BCAT and/or the accumulation of a metabolite pro-
duced by this enzyme in the mitochondria could determine a block of
the electron transport chain. In contrast, parasites overexpressing D-
LDH presented ΔΨm values similar to controls (Fig. 8), suggesting that
the activation of glycolytic and methylglyoxal pathways, in which this
enzyme is involved (Greig et al., 2009), does not signiﬁcantly inﬂuence
the mitochondrial activity.
In addition, since changes on the ΔΨm have been associated with
ROS production, which in turn are associated with cell death, it was
analyzed whether the overexpression of D-LDH and BCAT could be
related to protection of parasites from PBS-induced ROS production.
For this purpose, overall intracellular ROS levels were measured using
the cell-permeable probe H2DCFDA in WT + Lexsy, WT + D-LDH,
WT+ BCAT, and P lines (Fig. 9A). The results showed that WT+ Lexsy
parasites (control) incubated with PBS for 2 h exhibited a marked in-
crease in H2DCFDA ﬂuorescence signal (79.7 versus 9.3 of untreated
parasites; Fig. 9A), supporting an increased ROS production upon ex-
posure to nutritional stress induced by PBS. In contrast, when the P line
was exposed to PBS a 2.2-fold lower accumulation of the ﬂuorescent
probe than in control parasites was observed (Fig. 9A), indicating a
lower ROS production and/or a higher antioxidant response in the
PMM-resistant line regarding the control line, as expected from a P
resistant line (Garcia-Hernandez et al., 2012). Remarkably, levels of
ROS in the transfected D-LDH and BCAT Leishmania lines (WT + D-
LDH, WT + BCAT, respectively) were very low, and they did not sig-
niﬁcantly increase when the over-expressing parasites were incubated
in PBS (Fig. 9A). Thus, it can be concluded that Leishmania lines over-
expressing D-LDH or BCAT generated (or accumulated) lower ROS
amounts than control, and also than the P line (Fig. 9A), suggesting that
these enzymes, or their metabolites, are involved in metabolic processes
that increase the ability of parasites to neutralize the ROS production
induced by nutritional stress.
Additionally, considering that the major source of oxidants in eu-
karyotes is the mitochondria, we repeated the assays but using the
MitoSOX red dye, as a probe for measuring mitochondrial ROS levels.
As shown in panel B of Fig. 9, incubation of parasites in PBS also in-
duced a marked increase in MitoSOX red ﬂuorescence levels in the
control line versus untreated parasites, but not in Leishmania lines over-
expressing D-LDH or BCAT (Fig. 9B). Also, PMM-resistant parasites
accumulated 1.7-fold less probe than the control line after incubation
with PBS (Fig. 9B). The results indicated the ability of D-LDH and BCAT
proteins to protect Leishmania parasites against oxidative stress also
inside the mitochondria.
All these results suggest that suppression of mitochondrial activity
by the action of PMM (Maarouf et al., 1997) leads to an activation of
glycolytic activity as the most likely alternative for the production of
cellular ATP (Chawla et al., 2011). It has been reported that Leishmania
produce s limited amounts of D-lactate via the methylglyoxal pathway
(Darling and Blum, 1988). This pathway functions as an overﬂow of
glycolysis, in which triose-phosphates, formed in the glycolytic
pathway, are converted to inorganic phosphate and methylglyoxal.
Indeed the methylglyoxal pathway enzymes glyoxalase I (LinJ.35.3060)
and II (LinJ.12.0200) are present in L. infantum. The resulting D-lactate
would be converted to pyruvate by a D-LDH (LinJ.27.1940). The pyr-
uvate resulting from both the glycolytic and the methylglyoxal path-
ways may be converted by the enzymes of the TCA cycle into building
blocks for biosynthesis or acts as a scavenger of hydrogen peroxide,
helping to reduce the oxidative stress. The compromised mitochondrion
is likely to be crippled in its capacity for beta-oxidation of fatty acids
and therefore must resort to an increase in metabolism of the branched
Fig. 7. Stability of the resistance to PMM and levels of expression of D-LDH and BCAT in L. donovani P line. (A) The stability of resistance with respect to the
initial EC50 of P line (month 0) was determined at 2, 3, and 4 months after removal of the drug pressure, using an MTT-based assay, as described in Materials and
Methods. The results shown are the mean ± SD from three independent experiments. Asterisks denotes statistically signiﬁcant diﬀerences (p < 0.05;
Wilcoxon–Mann–Whitney test) between the P line before and after drug removal. (B) Relative expression levels of D-LDH and BCAT transcripts was determined by
RT-qPCR before and after 2, 3 and 4 months after removal of drug pressure. Total RNA from diﬀerent lines was extracted as described in Materials and Methods. Also,
RT-qPCR expression values of the genes were normalized with the expression level of GAPDH transcript. The expression levels of the transcripts in the P line was set
at 100%.The results shown are the mean ± SD from three independent experiments. Signiﬁcant diﬀerences versus the control (P line) were determined using
Student's t-test (*p < 0.01; **p < 0.005; ***p < 0.001).
Fig. 8. Mitochondrial membrane potential in diﬀerent Leishmania lines.
The diﬀerent L. donovani lines were left untreated (black columns) or exposed
to PBS (white columns) for 2 h. Promastigotes were labeled for 15 min with
0.5 μM of Rh123 as described in Materials and Methods. Measurements by ﬂow-
cytometry are expressed as mean of arbitrary ﬂuorescence units ± SD from
three independent experiments. Asterisks denotes statistically signiﬁcant dif-
ferences (p < 0.05; Wilcoxon–Mann–Whitney test) between the control line
(WT+ Lexsy) and both the P line and the BCAT- transfected line (WT+ BCAT).
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amino acids, leucine, isoleucine and valine. The BCAT is the ﬁrst en-
zyme of this oxidation pathway for all three amino acids. The resulting
succinyl-CoA and acetyl-CoA is then converted into necessary building
blocks for biosynthesis by the TCA cycle enzymes, or excreted as free
acetate with the additional advantage of the formation of an extra
molecule of ATP (Van Hellemond et al., 1998). Thus, under the pressure
of PMM, overexpression of D-LDH and BCAT may allow for the pro-
duction of additional energy in the form of ATP to compensate for
mitochondrial dysfunction. Consequently, overexpression of D-LDH and
BCAT could be considered as new molecular markers of drug resistance
to PMM in Leishmania that will require future studies of validation in
clinical and experimental resistant lines to PMM.
Apart from transcripts for these two enzymes, D-LDH and BCAT,
among the diﬀerential expression transcripts, we found the transcript
encoding for a member of the ABC family transporter (ABCA10; tran-
script LinJ.29.T0640) was present at higher levels (∼1.8-fold) in the P
line (see Supplementary ﬁle 1). It is noticeable that this protein was
found to be overexpressed in an L. donovani line resistant to di-
ﬂuoromethylornithine (Singh et al., 2014), and it may be postulated a
role of this transporter in PMM exclusion. In fact, many members of the
superfamily of ABC transporters have been found to be involved in drug
resistance (see above (Sauvage et al., 2009)). Taking into account that
ribosome would be another target for PMM (Fernandez et al., 2011;
Zhang et al., 2016), another up-regulated transcript worthy to note was
LinJ.03.T0240, coding for a ribosomal protein (L38). Finally, in the P
line, similar to that occurring in the S and A lines, transcripts encoding
for amastins (LinJ.29.T1450 and LinJ.29.T3000) were found to be up-
regulated. These results may be indicating that overexpression of
amastin genes in Leishmania might lead to an increased parasite ﬁtness
against the cellular stresses elicited by drugs.
4. Conclusions
Our study illustrates the battery of molecular adaptations exploited
by Leishmania to develop drug resistance, including gene over-expres-
sion, deletion, SNPs generating stop codons or ampliﬁcation of sets of
genes. This also further validates our approach (selection of drug re-
sistance followed by NGS analysis of whole genome and transcriptome)
as it allows the simultaneous identiﬁcation of gain-of- and loss-of-
function. Our study also highlights the power of the method, as it
identiﬁes in each line several genes that could be participating to drug
resistance and accompanying eﬀects (virulence for instance). Validation
of the candidate driver genes is essential and was done here for the
strongest candidates, for which largest diﬀerences in gene expression
were observed. This allowed to identify new drivers, like SMT, the
deletion of which being associated with resistance to AmB and the
tandem D-LDH-BCAT, the ampliﬁcation of which being related to PMM
resistance. Our results provide highly relevant results for the under-
standing of drug resistance in Leishmania, but also for the design of
molecular tools for its monitoring in clinical conditions.
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